Study Condition(s): Mild Alzheimer's, Mild Cognitive Impairment
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Participants With Early Alzheimer's Disease (AMARANTH)
Study Alias: AZES
The purpose of this study is to assess the efficacy and safety of LY3314814 compared with placebo in the treatment of early Alzheimer's disease.
This trial stopped recruiting or enrolling participants prematurely and will not start again. We are no longer examining or treating participants. The trial may have been stopped for many reasons. You may contact Lilly for further information.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have experienced gradual and progressive change in memory function for longer than 6 months or have been diagnosed with mild Alzheimer's disease or mild cognitive impairment
Participant must have a close friend, relative, or partner who is in regular contact and who would be willing to be a study partner throughout the study (for example, attend all study appointments and answer questions about the participant on the telephone)
Participant must not have significant neurological disease (such as Parkinson's disease, epilepsy, other dementias, or serious brain infections), other than Alzheimer’s Disease
Participant must not have a history of alcohol or drug abuse or dependence (except nicotine dependence) within the last 2 years
Participant must not have had any of the following within the past year: heart attack; moderate or severe congestive heart failure; hospitalization for chest pain; loss of consciousness due to low blood pressure or unexplained loss of consciousness; known significant structural heart disease or hospitalization for arrhythmia
Participant must not have a history of cancer within the last 5 years, with the exception of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, or non-progressive prostate cancer or other cancers with low-risk of recurrence or spread